X-Linked Hypophosphatemia Market Size was valued at USD 0.024 Billion in 2023. The Global X-Linked Hypophosphatemia industry is projected to grow from USD 0.26 Billion in 2024 to USD 0.03 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.34% during the forecast period (2024 - 2032).
X-linked hypophosphatemia (XLH) is an inherited disorder characterized by low levels of phosphate in the blood. The phosphate levels reduce as it is abnormally processed in the kidneys, which leads to the loss of phosphate through urine (phosphate wasting) and leads to soft and weak bones, causing rickets. XLH is usually diagnosed in childhood, and symptoms include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is caused by mutations in the PHEX gene on the X chromosome, and the inheritance of the X-linked is dominant.
The treatment generally involves supplements of phosphate and high-dose calcitriol (an active form of vitamin D) and may also include growth hormones and corrective surgery. The key factors responsible for driving the market are the increasing prevalence rates of XLH, growing awareness about XLH. However, negative psychological and emotional impacts of having X-linked hypophosphatemia, post-operative complications, unfavorable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures are hindering the growth of the X-linked hypophosphatemia market.
XLH is an inherited phosphate metabolism disorder in which inactivating mutations of the PHEX gene lead to local and systemic effects such as impaired growth, rickets, hearing difficulties, enthesopathy, osteomalacia, bone pain, bone abnormalities, spontaneous dental abscesses, osteoarthritis, and muscular dysfunction. Due to the rising cases of XLH in developing and developed economies, the global XLH market is expected to grow at a steady rate during the forecast period.
For instance, according to the European Journal of Endocrinology statistics published in 2016, the incidence of XLH has been estimated to be 3.9 per 100,000 live births and has a prevalence of 4.8 per 100,000 people. Also, according to the study published in May 2016 by NIHR Horizon Scanning Research & Intelligence Centre, XLH affected more than 500 children in the UK.
Similarly, according to the statistics published in 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US. And according to a report published in 2017 by the National Institute for Health and Care Excellence, there were approximately 250 children and young people with XLH in England, and up to 2,500 adults, till date. Thus, the overall market growth is projected to rise owing to the rising prevalence rates of XLH, which required adequate drugs and therapies for treatment.
The X-linked hypophosphatemia (XLH) market by treatment has been segmented into medication and Surgical or orthopedic treatment.
The X-linked hypophosphatemia market has been categorized by the end user into hospitals and clinics and research centers. The research centers segment is expected to account for the largest market share during the forecast period attributing to the increasing prevalence of XLH, increasing awareness regarding the disease, and growing research activity for its treatment.
The X-linked hypophosphatemia market, by region, is segmented into the Americas, Europe, Asia-Pacific, and RoW. Factors such as the increasing prevalence of XLH and increasing awareness about the disorder are anticipated to propel the growth of the X-Linked hypophosphatemia market.
The XLH market in the Americas is expected to hold a major market share owing to the growing prevalence of XLH in the US and Canada and the presence of a well-established healthcare sector. The rising research funding towards rare diseases such as XLH and the high healthcare expenditure is also expected to fuel the growth of the market during the forecast period.
For instance, Genome Canada and the Canadian Institutes for Health Research entered into a partnership to study rare genetic diseases by using Next-Generation Sequencing (NGS) technology. Similarly, the International Rare Diseases Research Consortium (IRDiRC) is a Scientific Secretariat that works in collaboration with Orphanet. Since 2010, IRDiRC financed over 3,000 projects.
Moreover, according to the statistics published in 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US. Moreover, the rising government funding for the healthcare sector, the increasing prevalence rate of rare diseases, and research funding are expected to propel the growth of the market in this region.
The prominent players in the X-linked hypophosphatemia market are
The players operating in the global X-linked hypophosphatemia (XLH) market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
| Report Attribute/Metric | Details |
| Market Size | USD 0.03 Billion |
| CAGR | 4.34% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Treatment and End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Ultragenyx Pharmaceutical, Validus Pharmaceuticals LLC, Prospec-Tany Technogene Ltd, Merck KGaA, Zeria Pharmaceutical Co., Ltd, Smith & Nephew, Narang Medical Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd |
| Key Market Opportunities | A recent drug approval by regulatory authorities are likely to offer lucrative opportunities for the growth of the market |
| Key Market Drivers | Rising cases of X-linked hypophosphatemia. Increasing awareness about XLH and the severity of the disease |
X-Linked Hypophosphatemia Market Highlights:
Frequently Asked Questions (FAQ) :
X-Linked Hypophosphatemia Market CAGR would be 3.20 during the forecast period.
X-Linked Hypophosphatemia Market valuation would be USD 0.03 Billion by 2032.
The research centers segment would X-Linked Hypophosphatemia Market.
The Americas would dominate X-Linked Hypophosphatemia Market
Players involved in X-Linked Hypophosphatemia Market are Validus Pharmaceuticals LLC, Ultragenyx Pharmaceutical, Merck KGaA, Prospec-Tany Technogene Ltd, Narang Medical Limited, Zeria Pharmaceutical Co., Ltd, Smith & Nephew, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, and Others.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
